English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduSince 1970, health care professionals have convened at the Society of Gynecologic Oncology (SGO)’s Annual Meeting on Women’s Cancer® to discuss the latest in gynecologic cancer care and science, receive educational programming, and network. Members of the entire gynecologic cancer care team who provide treatment and care in the areas of chemotherapy, radiation therapy, surgery, and palliative care attend the SGO Annual Meeting.
Tag: Gynecologic Cancer
The Foundation for Women’s Cancer to Host Free Patient and Advocates Education Forum in San Diego
The Foundation for Women’s Cancer (FWC) is pleased to host a free Patient and Advocate Education Forum on Friday, March 15, 2024, 10 a.m. – 4:30 p.m. PT, in San Diego, CA, at the San Diego Convention Center. The organization welcomes all gynecologic cancer (cervical, endometrial/uterine, ovarian, vaginal, and vulvar) patients, advocates, family members, and providers.
Using personalized medicine to target gynecological cancers
In this interview, Dr. Salani, who is also a professor of obstetrics and gynecology in the David Geffen School of Medicine at UCLA, talks about the latest research advances for these cancers and how women can help reduce their risk and help with the early detection of the five main types of gynecologic cancers: cervical, ovarian, uterine, vaginal and vulvar.
Foundation for Women’s Cancer Commemorates Gynecologic Cancer Awareness Month with Vital Educational Outreach and Resourceful Toolkit
The Foundation for Women’s Cancer (FWC) recognizes September as Gynecologic Cancer Awareness Month annually, and this year is sharing an array of impactful resources aimed at raising awareness about gynecologic cancers and promoting education. FWC provides free educational materials and informative trainings and webinars year-round, and this month will be featuring new and existing resources for those at risk to develop gyn cancer, as well as gyn cancer patients, caregivers, survivors, and health care professionals.
Pharmacologist: Cancer drug shortage is delaying lifesaving treatments
This year, an estimated 2 million Americans will be diagnosed with cancer. Now, a New York Institute of Technology pharmacology expert contends that these patients’ realities could grow increasingly harsher, as a monthslong shortage of chemotherapy drugs continues. Low supplies of…
TWO CLINICAL TRIALS REVEAL ADDITION OF IMMUNOTHERAPY TO CHEMOTHERAPY REGIMEN INCREASES PROGRESSION-FREE SURVIVAL IN ENDOMETRIAL CANCER PATIENTS
The results of two clinical trials, presented today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, showcased adding immunotherapy to standard chemotherapy resulted in significantly longer progression-free survival (PFS) among patients with advanced or recurrent endometrial cancer (EC).
TRIAL’S LONG-TERM FOLLOW-UP DATA SHOWS NO DIFFERENCE IN OVERALL SURVIVAL AMONG OVARIAN CANCER PATIENTS WHO DID AND DID NOT RECEIVE PARP INHIBITOR MAINTENANCE THERAPY
After resolving missing data burdens, the ENGOT-OV16/NOVA (NCT01847274) study data shows no difference in overall survival for platinum-sensitive recurrent ovarian cancer (PSROC) patients who received PARP inhibitor niraparib maintenance therapy (MT) and those who did not. Results from the trial were presented today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer by Ursula Matulonis, MD, of the Dana-Farber Cancer Institute.
CLINICAL TRIAL PARTICIPATION ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN OVARIAN CANCER PATIENTS
Clinical trial participation was associated with improved overall survival (OS) compared to standard of care therapy among women with platinum-resistant epithelial ovarian cancer (EOC), according to a research study presented today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.
STUDY FINDS INTRIGUING OUTCOMES IN OVARIAN CANCER PATIENTS TREATED WITH PARP INHIBITORS BEFORE SURGICAL INTERVENTION AND SUBSEQUENT CHEMOTHERAPY
Administering PARP inhibitor (PARPi) olaparib prior to surgical intervention and chemotherapy in ovarian cancer patients – a new approach – is feasible and resulted in favorable surgical options, managed adverse events, and positive health outcomes, according to results from the Neoadjuvant Olaparib Window (NOW) Trial presented today by Shannon Westin, MD et al. at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.
Study: Spice May Improve Ovarian Cancer Treatment
New research makes the case for why curcumin could help enhance treatment for ovarian cancer.
UC San Diego Health Experts Available during Endometriosis Awareness Month
With Bindi Irwin recently making headlines about her personal experience with endometriosis, experts at UC San Diego Health are available to discuss a variety of topics, including causes, symptoms and treatment options to manage the condition during Endometriosis Awareness Month…
Society of Gynecologic Oncology to Host 2023 Annual Meeting on Women’s Cancer® March 25-28 in Tampa, Florida
The 2023 SGO Annual Meeting on Women’s Cancer will be held Saturday, March 25 through Tuesday, March 28 at the Tampa Convention Center in Tampa, Florida. Meeting registration, presenters, session titles and details, press details, and more can be found at sgo.org/annual-meeting.
Patients with Both Gynecologic Cancer and COVID-19 at High Risk of Anti-Cancer Treatment Delays, Hospitalization and Death
Gynecologic oncology patients who are diagnosed with COVID-19 have a high risk of cancer treatment delays, hospitalization, and death, with non-White race further increasing adverse outcomes, according to the results of a new study.
AI Model Trained on Video Images Successfully Predicts Treatment Outcomes in Ovarian Cancer Patients
Artificial intelligence (AI) can predict treatment outcomes in ovarian cancer at the time of pre-surgical assessment with a high degree of accuracy, according to results of a new pilot study.
MD Anderson Research Highlights for September 22, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a new method to measure breast cancer response, a new immunotherapy approach for multiple myeloma, characterization of the immune landscape of cholangiocarcinoma, a new contrast agent to improve molecular imaging techniques, and new treatment targets in breast, gynecologic and pancreatic cancers.
Women’s Wellness: Types of Gynecologic Cancers and their Warning Signs
September is Gynecologic Cancer Awareness Month. Rutgers Cancer institute of New Jersey Gynecologic Oncology Chief Dr. James Aikins reminds women about the types of gynecologic cancers and their warning signs
Memorial Sloan Kettering Cancer Center Recognized as One of the Best Hospitals for Cancer Care by U.S. News & World Report for the 32nd Year in a Row; Ranked #1 Nationally for Ear, Nose, and Throat Care
Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the number two hospital for cancer care in the nation by U.S. News & World Report in its annual Best Hospitals listing. Since these prestigious rankings were established more than 30 years ago, MSK has consistently ranked among the top two cancer hospitals in the country.
Financial toxicity associated with cancer care impacts nearly 50% of women with gynecologic cancer
Researchers report on how a diverse cohort of gynecologic cancer patients are affected by financial distress, also called “financial toxicity” in acknowledgment of the health hazards it can pose, in the International Journal of Gynecological Cancer.
Internationally Renowned Breast Cancer and HIV-Associated Malignancy Expert to Join Mount Sinai
Mount Sinai Health System has recruited an internationally recognized expert in the management of breast cancer and HIV-associated malignancies, Joseph A. Sparano, MD, FACP, as Chief of Hematology and Medical Oncology and Deputy Director of The Tisch Cancer Institute (TCI). Dr. Sparano will also hold the Ezra M. Greenspan, MD Professorship in Clinical Cancer Therapeutics at the Icahn School of Medicine at Mount Sinai and will oversee the expansion of clinical and research capacities of the Division and TCI.
Percutaneous image guided thermal ablation safe, effective therapy for metastatic gynecologic cancers
New UCLA study shows that image guided needle based thermal ablation is a safe and effective approach for patients with localized metastatic gynecologic cancers throughout the body.
Leading Expert in Women’s Cancers Appointed Director of Gynecologic Oncology at Perlmutter Cancer Center
Nationally renowned surgeon and women’s cancers expert Leslie R. Boyd, MD, has been named director of the Division of Gynecologic Oncology
Jersey Shore University Medical Center Welcomes Gynecologic Oncologist Dr. Borowsky
Hackensack Meridian Jersey Shore University Medical Center recently welcomed gynecologic oncologist and surgeon Mark E. Borowsky, M.D., MBA, as director of the Division of Gynecologic Oncology.
MD Anderson and Mirati Therapeutics announce KRAS strategic research and development collaboration in solid tumors
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati’s two investigational small molecule, potent and selective KRAS inhibitors – adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents – which target two of the most frequent KRAS mutations in cancer.
Research News Tip Sheet: Story Ideas from Johns Hopkins Medicine
During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas from Johns Hopkins” every other Tuesday.
Ovarian Cancer Screening Study Focuses on Early Detection in Women at Low Risk
Atlantic Health System is enrolling women in a landmark study that uses a simple blood test for the CA-125 protein to screen women who are at low risk for ovarian cancer. The purpose of the clinical trial is to help determine whether this test can catch ovarian cancer early in women who would not normally be screened for it. Atlantic Health System hospitals are the only centers in the New York metro region to participate in the study, and have the third highest enrollment numbers in the nation.
Most Women Treated in New York City for Gynecologic Cancers Are Not at Increased Risk of Death From COVID-19
Women receiving standard treatment in New York City for ovarian, uterine, and cervical cancers are not at increased risk of being hospitalized for or dying from COVID-19 due to their cancer, a new study shows.
Memorial Sloan Kettering Named One of the Best Hospitals for Cancer Care by U.S. News & World Report for the 31st Year in a Row
Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the number two hospital for cancer care in the nation by U.S. News & World Report in its annual Best Hospitals listing.
Since U.S. News & World Report established the prestigious rankings more than 30 years ago, MSK has earned either the first or second spot for best cancer care in the country each year.
February is Cancer Prevention Month
Along with a healthy lifestyle, regular screening can help with the prevention of cancer. Rutgers Cancer Institute of New Jersey experts share additional information during this Cancer Prevention Month.
Expert Offers Insight on Sneaky Signs of Cervical Cancer
Dr. Teresa Diaz-Montes is a gynecologic surgeon who provides expertise in gynecologic cancers as well as minimally invasive surgical techniques. Teresa P. Diaz-Montes, M.D., MPH, FACOG, serves as the Associate Director of The Lya Segall Ovarian Cancer Institute. She also is a…
Two University of Chicago Medicine physicians elected to National Academy of Medicine for 2019
Two University of Chicago faculty members, Vineet Arora, MD, MAPP, and Ernst Lengyel, MD, PhD, have been elected to membership in the National Academy of Medicine.